Lambda256's Nodit Achieves SOC 2 Type II Certification, Validating Enterprise-Grade Blockchain Infrastructure Operations

SEOUL, South Korea, Feb. 2, 2026 /PRNewswire/ -- Lambda256, the blockchain technology subsidiary of Dunamu, announced that its enterprise blockchain infrastructure platform Nodit has achieved SOC 2 Type II certification, marking the first such certification in the Korean blockchain industry. The certification validates Nodit's security, availability, and operational controls against globally recognized standards, reinforcing its readiness to support institutional and enterprise use cases.

SOC 2 is an international compliance standard developed by the American Institute of Certified Public Accountants (AICPA). It evaluates how organizations safeguard and manage data across five trust service criteria: security, availability, processing integrity, confidentiality, and privacy. SOC 2 reports are issued in two forms: Type I, which assesses the design of internal controls at a specific point in time, and Type II, which verifies the effective operation of those controls over an extended period.

With this certification, Nodit's blockchain node infrastructure and data service operations have been independently audited and formally validated under SOC 2 Type II standards, confirming that its security and operational controls meet global compliance requirements on an ongoing basis.

Lambda256 has supported a wide range of production environments through Nodit, providing enterprise-grade blockchain infrastructure and Web3 data services to customers handling large-scale on-chain transactions. These customers include domestic and international digital asset exchanges, financial institutions, and gaming companies. With this achievement, Lambda256 becomes the only blockchain company in Korea to hold a SOC 2 Type II certification.

The SOC 2 evaluation was conducted in partnership with EY Korea. Lambda256 first obtained SOC 2 Type I certification for Nodit in November 2025, followed by a comprehensive review of control effectiveness over time, culminating in the issuance of the SOC 2 Type II final report.

In parallel, Lambda256 has launched a newly redesigned corporate website to clearly communicate its business scope, technical capabilities, and security posture to external stakeholders. The new website introduces Lambda256's core solutions, including Nodit, and outlines its security and compliance standards for financial and enterprise customers. A dedicated Trust Center provides access to the SOC 2 report and related compliance information.

" As blockchain technology enters regulated and institutional environments, stable operations, security, and internal controls have become essential capabilities for blockchain infrastructure providers," said Michael Cho, Head of Business at Lambda256. "SOC 2 Type II certification demonstrates that Lambda256 meets these requirements and has proven its operational maturity. We aim to be a trusted infrastructure partner that enables financial institutions to adopt blockchain technology with confidence."

He added, "Through blockchain node operations, on-chain data analytics, and compliance-ready digital asset infrastructure, we will continue to support the growth of institutional-grade digital asset services."

For the latest updates and security disclosures, visit Lambda256's Trust Center.

About Lambda256

Lambda256, the blockchain affiliate of Dunamu, is a leading Web3 technology company driving innovation across infrastructure, data, and digital finance. Since its spin-off in 2019, Lambda256 has built platforms that connect enterprises and developers to blockchain, including Nodit for infrastructure, Clair for data intelligence, and Scope for stablecoin issuance. With proven experience supporting financial institutions, global partners, and large-scale Web3 applications, Lambda256 continues to shape the future of digital transformation with enterprise-grade blockchain solutions.

Homepage l X (Twitter) l Linkedin

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Lambda256's Nodit Achieves SOC 2 Type II Certification, Validating Enterprise-Grade Blockchain Infrastructure Operations

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics.

Covalent small-molecule drugs have shown great success in cancer therapy by forming irreversible bonds with their targets. This has inspired efforts to extend covalent strategies to protein therapeutics, especially engineered miniproteins. However, their development is limited by a kinetic mismatch: Miniproteins are rapidly cleared in vivo, whereas covalent bond formation is typically slow. In addition, high-throughput platforms for systematically optimizing covalent protein reactivity have been lacking.

To address this challenge, the researchers proposed that precise spatial positioning of chemical warheads within protein scaffolds could enable molecular preorganization, thereby accelerating covalent bond formation without increasing intrinsic reactivity (Fig. 1).

Based on this concept, the team developed a high-throughput platform that combines yeast surface display with chemoselective protein modification to screen diverse crosslinkers and millions of protein variants. By optimizing warhead placement and the local chemical environment, the platform enables rapid and irreversible target engagement.

Using this platform, the researchers developed a covalent antagonist targeting PD-L1, termed IB101. Structural analysis revealed that IB101 forms a defined binding pocket that precisely positions the warhead in a reactive conformation, greatly accelerating covalent bond formation. Functionally, IB101 effectively blocks the PD-1/PD-L1 immune checkpoint pathway and demonstrates strong antitumor activity in mouse models. Notably, despite its short in vivo half-life, IB101 achieves durable target engagement and tumor suppression, outperforming conventional antibody-based therapies under comparable conditions.

The platform was further applied to cytokine engineering, leading to the development of a covalent IL-18 variant, IB201. This engineered cytokine rapidly forms a covalent interaction with its receptor, enhancing signaling strength and duration. In vivo studies showed that IB201 induces potent antitumor immune responses without detectable systemic toxicity. These results highlight the potential of covalent engineering to improve the efficacy and safety of cytokine-based therapies.

Beyond immunotherapy targets, the platform was also applied to develop a covalent inhibitor targeting the receptor-binding domain (RBD) of SARS-CoV-2. This molecule achieves durable viral neutralization, demonstrating the versatility of the approach across different therapeutic modalities.

This study establishes a general strategy for engineering fast-acting covalent protein therapeutics. By enabling covalent bond formation on timescales compatible with rapid in vivo clearance, the platform overcomes a fundamental limitation in the field.

These findings provide a new framework for designing biologics with both rapid kinetics and sustained target engagement, with broad implications for cancer immunotherapy, antiviral therapy, and beyond.

Media Contact: 

Chi Zhang
media@westlake.edu.cn 
+86-15659837873

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Fast-Acting Covalent Protein Drugs From a New High-Throughput Platform